For the year ending 2025-12-31, BCYC had -$251,352K decrease in cash & cash equivalents over the period. -$252,025K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -218,960 |
| Share-based compensation expense | 39,464 |
| Depreciation and amortization | 6,422 |
| Deferred income tax (benefit) provision | -850 |
| Research and development incentives receivable | -2,892 |
| Prepaid expenses and other assets | 5,816 |
| Operating lease rightofuse assets | -4,597 |
| Accounts payable | -6,871 |
| Accrued expenses and other current liabilities | 4,093 |
| Operating lease liabilities | -5,456 |
| Deferred revenue | -69,190 |
| Net cash used in operating activities | -249,675 |
| Purchases of property and equipment | 2,350 |
| Net cash used in investing activities | -2,350 |
| Proceeds from the exercise of share options and settlement of restricted share units | 37 |
| Principal payments on finance lease obligations | 168 |
| Net cash (used in) provided by financing activities | -131 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 804 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -251,352 |
| Cash, cash equivalents and restricted cash at beginning of period | 880,067 |
| Cash, cash equivalents and restricted cash at end of period | 628,715 |
BICYCLE THERAPEUTICS PLC (BCYC)
BICYCLE THERAPEUTICS PLC (BCYC)